foxo4-dri peptide senolytic human trial Buy (Proxofim) Senolytics: from pharmacological inhibitors to
Senolytics: from pharmacological inhibitors to immunotherapies, a promising future for patients' treatment npj Aging The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4 DRI Nature Communications FOXO4 DRI: Human Trial Status, Cancer Research & Senolytic Data Molecular modelling of the FOXO4 TP53 interaction to design senolytic peptides for the elimination of senescent cancer cells eBioMedicine
Pay in 4 interest-free payments of $5.76 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 1 - Aug 6



